Wednesday, 23 March 2016

### **COMPANY RESULTS**

# Scientex (SCI MK)

2QFY16: Earnings Above Expectations; Proposes Bonus Issue

Scientex's 2QFY15 results were above expectations. 2QFY16 core net profit rose 46.4% yoy driven by its manufacturing segment which saw a huge EBIT margin expansion of 5.8ppt, and a lower effective tax rate of 16.5% (2QFY15: 21.5%). We note that the huge margin expansion achieved since 1QFY16 may contract slightly from the recent ringgit strengthening. Scientex has also proposed a 1-for-1 bonus issue. Maintain BUY on weakness with a higher SOTP-based target price of RM14.40.

### **2QFY16 RESULTS**

| Year to 31 Jul  | 2Q16  | qoq %   | yoy %   | 1H16    | yoy %   |
|-----------------|-------|---------|---------|---------|---------|
| (RMm)           |       | chg     | chg     |         | chg     |
| Turnover        | 545.4 | (0.9)   | 17.8    | 1,096.0 | 22.6    |
| -Manufacturing  | 402.0 | 2.5     | 22.9    | 794.0   | 22.7    |
| -Property       | 143.4 | (9.5)   | 5.6     | 302.0   | 22.5    |
| EBIT            | 78.6  | (4.3)   | 63.6    | 160.6   | 79.5    |
| -Manufacturing  | 44.6  | 17.3    | 155.5   | 82.6    | 156.9   |
| -Property       | 36.4  | (23.4)  | (9.7)   | 83.9    | 16.1    |
| Forex loss/gain | (2.4) | (30.1)  | (75.1)  | (5.9)   | (60.7)  |
| Finance costs   | (2.6) | (15.7)  | 39.0    | (5.7)   | 50.5    |
| PBT             | 79.9  | (1.1)   | 68.8    | 160.6   | 83.7    |
| Core net profit | 67.0  | 4.2     | 46.4    | 131.4   | 61.6    |
| Margins         | (%)   | +/- ppt | +/- ppt | (%)     | +/- ppt |
| EBIT            | 14.4  | (0.5)   | 4.0     | 14.7    | 4.6     |
| -Manufacturing  | 11.1  | 1.4     | 5.8     | 10.4    | 5.4     |
| -Property       | 25.4  | (4.6)   | (4.3)   | 27.8    | (1.5)   |
| PBT             | 14.6  | (0.0)   | 4.4     | 14.7    | 4.9     |
| Core net profit | 12.3  | 0.6     | 2.4     | 12.0    | 2.9     |

Source: Scientex, UOB Kay Hian

### **RESULTS**

• Scientex's 2QFY16 results were above our and consensus' expectations, with core 1HFY16 net profit of RM131.4m (after stripping off RM5.9m forex loss from paring down its US dollar-denominated loans) representing 53% and 57% of the respective forecasts. Scientex's net profit in 1H is seasonally weaker, and historically accounts for 44-46% of full-year net profit. 2QFY16 core net profit rose 46.4% qoq due to its manufacturing segment which registered a big EBIT jump of 155.5% yoy despite a 22.9% yoy increase in sales, driven by a significant 5.8ppt EBIT margin expansion to 11.1%, as well as a lower effective tax rate of 16.5% (2QFY15: 21.5%) due to utilisation of reinvestment allowance.

## **KEY FINANCIALS**

| Year to 31 Jul (RMm)          | 2014  | 2015  | 2016F | 2017F | 2018F  |
|-------------------------------|-------|-------|-------|-------|--------|
| Net turnover                  | 1,590 | 1,802 | 2,356 | 3,081 | 3,798  |
| EBITDA                        | 229   | 269   | 397   | 473   | 543    |
| Operating profit              | 190   | 225   | 345   | 418   | 485    |
| Net profit (rep./act.)        | 148   | 158   | 261   | 315   | 367    |
| Net profit (adj.)             | 146   | 173   | 267   | 315   | 367    |
| EPS (sen)                     | 63.4  | 75.1  | 116.2 | 136.9 | 159.4  |
| PE (x)                        | 20.4  | 17.2  | 11.1  | 9.5   | 8.1    |
| P/B (x)                       | 4.2   | 3.2   | 2.7   | 2.2   | 1.9    |
| EV/EBITDA (x)                 | 13.7  | 11.7  | 7.9   | 6.7   | 5.8    |
| Dividend yield (%)            | 1.6   | 1.7   | 2.6   | 3.1   | 3.6    |
| Net margin (%)                | 9.3   | 8.8   | 11.1  | 10.2  | 9.7    |
| Net debt/(cash) to equity (%) | 36.0  | 14.3  | 9.9   | (0.9) | (11.1) |
| Interest cover (x)            | 32.1  | 32.6  | 65.7  | 70.9  | 104.6  |
| ROE (%)                       | 22.1  | 19.1  | 25.4  | 25.7  | 25.1   |
| Consensus net profit          | -     | -     | 232   | 272   | 325    |
| UOBKH/Consensus (x)           | -     | -     | 1.15  | 1.16  | 1.13   |

Source: Scientex, Bloomberg, UOB Kay Hian

n.m. : not meaningful; negative P/E, EV/EBITDA reflected as "n.m."

## **BUY**

## (Maintained)

| Share Price  | RM12.94  |
|--------------|----------|
| Target Price | RM14.40  |
| Upside       | +11.3%   |
| (Previous TP | RM12.50) |

## **COMPANY DESCRIPTION**

Scientex is one of the largest industrial packaging companies in the world and a niche property developer in Southern Malaysia.

## STOCK DATA

| GICS sector                     | Materials |
|---------------------------------|-----------|
| Bloomberg ticker:               | SCI MK    |
| Shares issued (m):              | 229.5     |
| Market cap (RMm):               | 2,969.5   |
| Market cap (US\$m):             | 740.6     |
| 3-mth avg daily t'over (US\$m): | 8.0       |
|                                 |           |

### Price Performance (%)

| 52-week high/low |               |      | RM12.94 | 1/RM6.58 |
|------------------|---------------|------|---------|----------|
| 1mth             | 3mth          | 6mth | 1yr     | YTD      |
| 20.7             | 36.1          | 83.5 | 94.3    | 32.7     |
| Major Sh         | areholders    |      |         | %        |
| Scientex H       | oldings Sdn E | Bhd  |         | 21.6     |
| Scientex Le      | easing Sdn B  |      | 10.2    |          |
| Lim Teck M       | leng Sdn Bho  |      | 8.2     |          |
|                  |               |      |         |          |
| FY16 NAV/        | Share (RM)    |      |         | 4.86     |
| FY16 Net D       | Debt/Share (F | RM)  |         | 0.48     |

## PRICE CHART



Source: Bloomberg

ANALYST

Fong Kah Yan +603 2147 1993 kahyan@uobkayhian.com



Wednesday, 23 March 2016

- Proposes a 1-for-1 bonus issue. Scientex has announced a 1-for-1 bonus issue which
  is slated for completion by 3Q16. We are positive on the news as it would help improve
  liquidity of Scientex's shares.
- All eyes on the manufacturing segment. Although 2QFY16 sales grew 22.9% yoy, its
  EBIT recorded a huge jump of 155.5% yoy driven by significant margin expansion of
  5.8ppt. This was achieved on the back of: a) higher consumer packaging sales mix which
  yielded better margins than that of industrial packaging, b) stronger US\$/RM, and c)
  operating efficiency and better economies of scale. In 2QFY16, the consumer packaging:
  industrial packaging sales mix stood at 47%:53% (2QFY15: 40%:60%)
- Property segment continues to be resilient in a weak property market. In 2QFY16, EBIT was down by 9.7% yoy despite a marginal increase in sales. This was due to a 4.3ppt contraction in EBIT margin attributed to the higher proportion mix of high-rise properties which yielded lower margins in 2QFY16. As at end-Jan 16, unbilled sales amounted to RM630.2m (end-Jul 15: RM584.9m) and is set to be recognised over the next two to three years. We also understand from management that the take-up rate for its property launches in the first six months of FY16 had remained healthy at 80-85%.

#### STOCK IMPACT

- More production to come on stream from manufacturing segment in 2H16... Scientex has begun to ramp up of utilisation at its new cast polypropylene (CPP) film plant in Malacca with a production capacity of 12,000 MT p.a. The biaxially-oriented polypropylene (BOPP) plant in Pulau Indah will kick off by mid-16. This will raise BOPP production capacity to 60,000 MT p.a. from 6,000 MT p.a currently. Scientex will also invest RM21m to install three more polyethylene (PE) film production lines at its Rawang plant by mid-16, which will raise total capacity to 74,400 MT p.a. from 62,400 MT p.a.
- ...with further expansion in the pipeline. Scientex has earmarked RM30m capex to expand production capacity by 50% at its recently-acquired Scientex Great Wall Ipoh (SGWI) by end-16/early-17. SGWI is principally involved in the manufacturing of downstream specialty consumer packaging films and film-based components including form-fill-seal (FFS) bags. The acquisition has enabled Scientex to leverage on SGWI's major existing clientele such as Procter & Gamble to penetrate export markets like Japan, Indonesia, the Philippines, Thailand and India.
- More plans in the pipeline for property segment too. In Jan 16, Scientex completed the acquisition of a 326-acre land in Pulai for RM219m (at approximately RM15.40 psf), which will increase its landbank to 1,200 acres (from 870 acres currently). Management has planned a mixed development project with an estimated GDV of RM3b to be launched over a period of 10 years. Meanwhile, management will be launching the first phase of the development consisting of double-storey terrace houses priced at RM300,000-400,000 in Jul 16.

## **EARNINGS REVISION/RISK**

• In view of the stronger-than-expected earnings, we raise our earnings forecasts by 6.4-7.8% for FY16-18F after updating our sales and margin assumptions. As at end-Jan 16, US dollar borrowings stood at RM125.5m (21.6% of total borrowings).

### VALUATION/RECOMMENDATION

• Maintain BUY with a higher SOTP-based target price of RM14.40, based on a 13x (from 12x) 2017F EPS for the manufacturing segment and an unchanged 6x 2017F EPS for the property segment. A 13x PE for its manufacturing segment is conservatively lower as compared with listed consumer packaging companies such as Daibochi and Tomypak which are trading at 2017F PE 13-17x. Our target price implies a 9.9x FY17F PE.

## SOTP VALUATION

|                                       | 2017 Net Profit (RMm) | PE (x) | Fair Value (RMm) |
|---------------------------------------|-----------------------|--------|------------------|
| Manufacturing                         | 183.9                 | 13     | 2,390.6          |
| Property                              | 152.5                 | 6      | 914.9            |
| Total                                 | 336.4                 |        | 3,305.5          |
| Current Outstanding No. of Shares (m) |                       |        | 230.0            |
| Target Price (RM)                     |                       |        | 14.40            |
| Source: UOB Kay Hian                  |                       |        |                  |

### **EARNINGS REVISION**

| EPS   | yoy                     |
|-------|-------------------------|
| (sen) | % chg                   |
| 116.2 | 54.6                    |
| 136.9 | 17.8                    |
| 159.4 | 16.4                    |
|       | (sen)<br>116.2<br>136.9 |


Source: UOB Kay Hian

## SALES BY SEGMENT



Source: Scientex, UOB Kay Hian

#### **EBIT BY SEGMENT**



Source: Scientex, UOB Kay Hian

### **KEY ASSUMPTIONS**

|                 | FY16F   | FY17F   | FY18F   |
|-----------------|---------|---------|---------|
| Sales           | 2,356.4 | 3,080.8 | 3,798.3 |
| Manufacturing   | 1,751.4 | 2,390.9 | 3,062.0 |
| Property        | 605.0   | 689.9   | 736.3   |
| EBIT margin (%) |         |         |         |
| Manufacturing   | 9.4     | 9.1     | 9.1     |
| Property        | 29.8    | 29.0    | 28.0    |

Source: Scientex, UOB Kay Hian



| Regional                      | M o r | n ı n | ı g ı | N O t | e s                        | Wednesday, 23 | March 2 | 016   |       |
|-------------------------------|-------|-------|-------|-------|----------------------------|---------------|---------|-------|-------|
| PROFIT & LOSS                 |       |       |       |       | BALANCE SHEET              |               |         |       |       |
| Year to 31 Jul (RMm)          | 2015  | 2016F | 2017F | 2018F | Year to 31 Jul (RMm)       | 2015          | 2016F   | 2017F | 2018F |
| Net turnover                  | 1,802 | 2,356 | 3,081 | 3,798 | Fixed assets               | 643           | 713     | 758   | 800   |
| EBITDA                        | 269   | 397   | 473   | 543   | Other LT assets            | 334           | 334     | 334   | 334   |
| Deprec. & amort.              | 44    | 52    | 55    | 58    | Cash/ST investment         | 91            | 235     | 297   | 381   |
| EBIT                          | 225   | 345   | 418   | 485   | Other current assets       | 570           | 713     | 880   | 1,043 |
| Associate contributions       | 4     | 4     | 5     | 5     | Total assets               | 1,638         | 1,995   | 2,269 | 2,559 |
| Net interest income/(expense) | (8)   | (6)   | (7)   | (5)   | ST debt                    | 150           | 270     | 210   | 130   |
| Pre-tax profit                | 221   | 343   | 416   | 485   | Other current liabilities  | 350           | 404     | 516   | 626   |
| Tax                           | (59)  | (76)  | (94)  | (109) | LT debt                    | 76            | 76      | 76    | 76    |
| Minorities                    | (4)   | (7)   | (7)   | (9)   | Other LT liabilities       | 57            | 57      | 57    | 57    |
| Net profit                    | 158   | 261   | 315   | 367   | Shareholders' equity       | 942           | 1,119   | 1,334 | 1,584 |
| Net profit (adj.)             | 173   | 267   | 315   | 367   | Minority interest          | 63            | 69      | 77    | 86    |
|                               |       |       |       |       | Total liabilities & equity | 1,638         | 1,995   | 2,269 | 2,559 |
| CASH FLOW                     |       |       |       |       | KEY METRICS                |               |         |       |       |
| Year to 31 Jul (RMm)          | 2015  | 2016F | 2017F | 2018F | Year to 31 Jul (%)         | 2015          | 2016F   | 2017F | 2018F |
| Operating                     | 190   | 257   | 319   | 376   | Profitability              |               |         |       |       |
| Pre-tax profit                | 221   | 343   | 416   | 485   | EBITDA margin              | 14.9          | 16.8    | 15.3  | 14.3  |
| Tax                           | (44)  | (76)  | (94)  | (109) | Pre-tax margin             | 12.3          | 14.6    | 13.5  | 12.8  |
| Deprec. & amort.              | 44    | 52    | 55    | 58    | Net margin                 | 8.8           | 11.1    | 10.2  | 9.7   |
| Working capital changes       | (34)  | (63)  | (58)  | (57)  | ROA                        | 10.4          | 14.4    | 14.8  | 15.2  |
| Other operating cashflows     | 3     | 0     | 0     | 0     | ROE                        | 19.1          | 25.4    | 25.7  | 25.1  |
| Investing                     | (37)  | (150) | (100) | (100) |                            |               |         |       |       |
| Capex (growth)                | (107) | (150) | (100) | (100) | Growth                     |               |         |       |       |
| Investments                   | (24)  | 0     | 0     | 0     | Turnover                   | 13.3          | 30.8    | 30.7  | 23.3  |
| Proceeds from sale of assets  | 13    | 0     | 0     | 0     | EBITDA                     | 17.3          | 47.5    | 19.2  | 14.9  |
| Others                        | 81    | 0     | 0     | 0     | Pre-tax profit             | 18.6          | 55.4    | 21.1  | 16.6  |
| Financing                     | (146) | 37    | (157) | (192) | Net profit                 | 6.6           | 65.2    | 20.5  | 16.4  |
| Dividend payments             | (48)  | (78)  | (92)  | (107) | Net profit (adj.)          | 18.5          | 54.6    | 17.8  | 16.4  |
| Issue of shares               | 0     | 0     | 0     | 0     | EPS                        | 18.5          | 54.6    | 17.8  | 16.4  |
| Proceeds from borrowings      | 0     | 180   | 0     | 0     |                            |               |         |       |       |
| Loan repayment                | (121) | (60)  | (60)  | (80)  | Leverage                   |               |         |       |       |
| Others/interest paid          | 23    | (4)   | (5)   | (5)   | Debt to total capital      | 18.3          | 22.5    | 16.8  | 11.0  |
|                               |       |       |       |       | L                          |               |         |       |       |

Net debt/(cash) to equity

Debt to equity

Interest cover (x)

23.9

14.3

32.6

30.9

9.9

65.7

21.4

(0.9)

70.9

13.0

(11.1)

104.6

7

84

0

91

144

91

0

235

62

235

297

0

84

297

381

0

Net cash inflow (outflow)

Changes due to forex impact

Ending cash & cash equivalent

Beginning cash & cash equivalent



Wednesday, 23 March 2016

#### **Disclosures/Disclaimers**

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

## IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.



Wednesday, 23 March 2016

## **Analyst Certification/Regulation AC**

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

| ollowing table.   |   |
|-------------------|---|
| General           | This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.  |
| Hong Kong         | This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note:  (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and  (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law. |
| Indonesia         | This report is distributed in Indonesia by PT UOB Kay Hian Securities, which is regulated by Financial Services Authority of Indonesia (OJK). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.   |
| Malaysia          | Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.  |
| Singapore         | This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.   |
| Thailand          | This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.  |
|                   |   |
| United            |   |
| United<br>Kingdom | This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.   |
|                   | This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in  |
| Kingdom           | This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.   |
| Kingdom<br>United | This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.  This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S.  |

Copyright 2016, UOB Kay Hian Pte Ltd. All rights reserved.

http://research.uobkayhian.com

RCB Regn. No. 197000447W